H.I.G. Capital, a private investment firm with over $8.5 billion under management, announced the closing of its second life sciences fund, H.I.G. BioVentures II, on April 10th. The diversified life science fund, which built on the success of its predecessor fund, targeted $250 million and was oversubscribed at $268 million.
H.I.G. BioVentures II will be headed by managing directors Aaron Davidson, Bruce Robertson, and Michael Wasserman. More than half of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?